MedPath

UPSHER-SMITH LABORATORIES

🇺🇸United States
Ownership
-
Established
1919-01-01
Employees
-
Market Cap
-
Website
http://www.upsher-smith.com/

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Phase 4
Recruiting
Conditions
Migraine Disorders
Interventions
Drug: Placebo
First Posted Date
2021-02-10
Last Posted Date
2025-01-27
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
132
Registration Number
NCT04748601
Locations
🇺🇸

Upsher-Smith Clinical Trial Site #5, Birmingham, Alabama, United States

🇺🇸

Upsher-Smith Clinical Trial Site #15, La Jolla, California, United States

🇺🇸

Upsher-Smith Clinical Trials Site #3, Aurora, Colorado, United States

and more 12 locations

Vogelxo(R) ABPM Study in Hypogandal Men

Phase 4
Completed
Conditions
Hypogonadism, Male
Interventions
First Posted Date
2020-09-22
Last Posted Date
2024-10-18
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
122
Registration Number
NCT04558567
Locations
🇺🇸

Upsher-Smith Clinical Trial Site #6, Birmingham, Alabama, United States

🇺🇸

Upsher-Smith Clinical Trial Site #2, Anaheim, California, United States

🇺🇸

Upsher-Smith Clinical Trial Site #1, Miami, Florida, United States

and more 4 locations

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

Phase 2
Completed
Conditions
Migraine Headaches
Interventions
Other: Sumatriptan Placebo Nasal Spray
First Posted Date
2016-08-05
Last Posted Date
2021-03-30
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
107
Registration Number
NCT02856802
Locations
🇺🇸

Site 30, San Diego, California, United States

🇺🇸

Site 11, Santa Monica, California, United States

🇺🇸

Site 31, Boston, Massachusetts, United States

and more 6 locations

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Phase 3
Completed
Conditions
Epilepsy
Interventions
First Posted Date
2010-08-30
Last Posted Date
2015-02-23
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
210
Registration Number
NCT01191086

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Placebo
First Posted Date
2010-06-11
Last Posted Date
2014-05-22
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
249
Registration Number
NCT01142193

Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms

Phase 3
Completed
Conditions
Postmenopausal Symptoms
First Posted Date
2008-08-01
Last Posted Date
2008-09-26
Lead Sponsor
Upsher-Smith Laboratories
Target Recruit Count
495
Registration Number
NCT00727129
© Copyright 2025. All Rights Reserved by MedPath